Regeneron completes acquisition Of Decibel Therapeutics, adding Promising Gene Therapy Programs For Hearing Loss
The acquisition of Decibel builds on prior collaboration between the companies and includes three ongoing gene therapy programs…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
26 Sep 23
The acquisition of Decibel builds on prior collaboration between the companies and includes three ongoing gene therapy programs…
26 Sep 23
Phase III NETTER-2 trial met primary endpoint of improvement in progression-free survival (PFS) and key secondary endpoint of…
25 Sep 23
Under the expanded partnership, scientists at the ICR’s Centre for Cancer Drug Discovery will work with researchers at…
25 Sep 23
The approval was based on the data from the EMPA-KIDNEY trial in which Jardiance showed a 28% relative…
25 Sep 23
The EC approval was based on findings from the Phase 2/3 trial conducted in collaboration with the Children’s…
25 Sep 23
Compared to chemotherapy, the combination met its dual primary endpoints of overall survival and progression-free survival showing a…
25 Sep 23
First Phase III results in breast cancer for AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan
25 Sep 23
The development marks an exciting new future for the brand, with more opportunities for visitors and exhibitors at…
25 Sep 23
Chime Biologics and Panolos Bioscience have entered into a global strategic collaboration agreement on a novel multi-specific protein…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
22 Sep 23
The deal will enable Glenmark Pharma to concentrate on its line of branded drugs for the treatment of…